Image may differ from actual product
The Business:
Manufacturer:	Merck & Co., Inc.
Merck & Co., Inc.'s total sales 2018:	$42.3 billion. Reference: Facts about Merck
Merck & Co., Inc.'s vaccine sales 2018:	$6.8 billion. Reference: 2018 Annual Report p 124
GARDASIL® 9's global sales in 2018:	$3,151 million. Reference: 2018 Annual Report p 124
British Columbia Center for Disease Control expense, F/Y 2018/19 for GARDASIL® 9	$6,570,894 Reference: BCCDC FOIA request by TMOV, 12-06-19
The Product:
Description of Vaccine:	Human Papillomavirus 9-valent Vaccine, Recombinant
	Active Immunizing Agent
Type of vaccine:	HPV. Given by Intramuscular injection
Primary medical reference:	Package insert for Canada

Notes:

Note 1- USA - Definition of serious adverse events: According to the CDC's Vaccine Adverse Events Reporting System (VAERS), events are classified as serious when any of the following outcomes are associated with the event: Death, Permanent Disability, Life Threatening, Hospitalized, Existing Hospitalization Prolonged, Congenital Anomaly or Birth Defect.

Note 2- United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - last month, CDC WONDER On-line Database. Accessed at http://wonder.cdc.gov/vaers.html on Sep 28, 2019 1:51:20 AM. A most user-friendly interface for you to access the VAERS database is here. It is presented by the National Vaccine Information Center and is called MedAlerts.

Note 3- VICP is the National Vaccine Injury Compensation Program, Monthly Statistics Report

Note 4- Canada - Definition of serious Adverse Events Following Immunization are those which are life-threatening, result in hospitalization or a prolongation of hospitalization, result in persistent or significant disability, or where the outcome is a birth defect or death, as defined by the World Health Organization. Source: Adverse Events Following Immunization (AEFI) Bi-annual Report from July 1 to December 31, 2018. and Adverse Events Following Immunization (AEFI) Bi-annual Report from January 1 to June 30, 2018.